Novartis AG ADR (NVS) Unusual Options Activity Today

Checking NVS unusual options activity helps you spot when traders are making outsized bets on Novartis AG ADR before the broader market catches on. Novartis AG ADR's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor NVS unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching NVS unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking NVS unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and NVS unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives.

It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Catalysts rarely arrive without a footprint, and NVS unusual options activity is often where that footprint shows up first. Our scanner tracks Novartis AG ADR's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at NVS unusual options volume on the call side or chasing put sweeps, Novartis AG ADR's unusual options flow today is one click away, so put it on your radar before the headlines hit.